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Our knowledge about various inherited and acquired causes of thrombophilic disorders has increased signiﬁcantly during
the past decade. Technology for various diagnostic tests for these rare disorders has matched the rapid advances in our
understanding about the thrombophilic disorders. Inherited thrombophilic disorders predispose young patients for various
venous or arterial thrombotic and thromboembolic episodes. Our understanding has also improved about various gene-gene
and gene-environment interactions and their impact on the resultant heterogenous clinical manifestations. We describe various
thrombophilic disorders, their diagnostic tests, pathogenic potential in isolation or with other concurrent inherited/acquired
defects and possible therapeutic and prophylactic strategies. Better understanding, optimal diagnostic and screening protocols
are expected to improve the diagnostic yield and help to reduce morbidity, disability, and mortality in relatively younger patients
harbouring these inherited and acquired thrombophilic disorders.
1.Introduction
Ischemic stroke (IS) is a common cause of morbidity and
mortality with signiﬁcant socioeconomic impact especially
when it aﬀects young patients. The incidence of ischemic
stroke varies from 3 to 23 per 100,000 among the young IS
suﬀerers [1]. Although the cutoﬀ age for deﬁning young IS
remainsdebatable,itisgenerallybelievedthattheriskfactors
andunderlying etiologies tendtobecomesimilartotheolder
patients at around 44 years of age. Therefore, most of the
studies deﬁne “stroke in young” as occurring in patients at
age 44 years or less [2]. Young strokes generate immense
interest among the stroke neurologists even when a larger
proportion of patients continue to be classiﬁed as “stroke of
undetermined etiology” [2].
Compared to the older adults, the incidence, risk factors,
and etiology are distinctly diﬀerent in younger IS. Accord-
ingly, cardioembolism (20%–35%), dissection of extracra-
nial arteries (6%–25%), drugs (10%), and hypercoagulable
states (5%–10%) are relatively more commonly detected in
younger IS patients [3–5]. Furthermore, additional factors
such as migraine, pregnancy and oral contraceptive use are
observed with higher frequency [4, 5].
Young IS attracts a barrage of diagnostic tests, mainly
searching for an underlying thrombophilic state. We discuss
various thrombophilic disorders, their available diagnostic
tests and signiﬁcance of testing for these uncommon causes.
2. Thrombophilic Disorders and
Ischemic Stroke
Thrombophilic states are disorders of hemostatic mecha-
nisms that result in a predisposition to thrombosis [6].
Thrombophilia is an established causeof venous thrombosis.
Therefore,itistemptingtoassumethatthesedisordersmight
have a similar relationship with arterial thrombosis. How-
ever, thrombophilia, alone, rarely causes arterial occlusions.
Even in individuals with a positive thrombophilia screen and
arterial thrombosis, the former might not be the primary
etiological factor [7]. Although thrombophilic disorders and
their contribution to the stroke risk are uncommon, their
detection often helps in management decisions, long-term
prognostication, screening family members “at-risk”, and
possible primary prophylaxis.
Thrombophilic disorders can be broadly divided into
inherited or acquired conditions. Inherited thrombophilic
disorders are far less commonly observed in young IS.
These include deﬁciencies of natural anticoagulants such as
proteinC,proteinS,andantithrombinIII(ATIII)deﬁciency,2 Stroke Research and Treatment
polymorphisms causing resistance to activated protein C
(Factor V Leiden mutation), and disturbance in the clotting
balance (prothrombin gene 20210G/A variant). Of all the
inheritedthrombophilicdisorders,FactorVLeidenmutation
is perhaps the commonest cause, accounting for about half
of the cases. Prothrombin gene mutation, protein C, protein
S deﬁciency, and antithrombin deﬁciency account for most
of the remaining cases. On the contrary, acquired throm-
bophilic disorders are more common and include conditions
such as the antiphospholipid syndrome, associated with
lupus anticoagulant and anticardiolipin antibodies.
In general, primary thrombophilic disorders contribute
to about 1%–4% of ischemic strokes. However, the preva-
lence varies widely between diﬀerent ethnic groups, age, and
geographic distributions. An exhaustive 15-years follow-up
study of 150 families with diﬀerent inherited thrombophilic
disorders failed to demonstrate any association between
these coagulation defects and arterial thrombosis [8]. How-
ever, these inherited thrombophilias were associated with
a high incidence of venous thrombosis, conferring almost
100% risk of deep vein thrombosis (DVT) in protein S
deﬁciency. DVT with or without pulmonary embolism was
the most frequent type of thrombosis. Similar observations
were reported in a case-control study that looked at the
association between inherited thrombophilic disorders and
acute IS [7]. It found that 1 in 7 patients with ﬁrst-
ever acute IS had a positive test for at least one of the
thrombophilias. However, this relationship was considered
coincidental instead of an actual cause of stroke for all the
IS subtypes, even when adjusted for age [6].
3. Thrombophilic Disorders
3.1. Factor V Leiden. Although factor V Leiden mutation
accounts for almost half of the thrombophilic states, its
prevalence varies among diﬀerent ethnic groups. It is more
commonly seen in Caucasians (prevalence 1% to 8.5%).
H o w e v e r ,F a c t o rVL e i d e nm u t a t i o nh a sb e e nr e p o r t e dr a r e l y
among patients of Chinese, Japanese, and African descent
[8, 9]. Although this mutation predisposes to a higher risk
of venous thrombosis, its association with arterial disease
remains unestablished for myocardial infarction as well as
IS [9]. In a study of 203 young IS patients, Nedeltchev et
al. reported 0.9% incidence of Factor V Leiden mutation
[10].
3.2. Prothrombin G20210A Mutation. Wide variations are
observed in the geographic and ethnic prevalence of pro-
thrombin (factor II) G20210A gene mutation. Similar to the
FactorVLeiden,thismutationisalsorareinpatientsofAsian
and African descent, but occurs in about 0.7% to 4.0% of
the Caucasians [11]. Although Prothrombin gene mutation
is not considered a risk factor for IS in the older populations,
an association has been suggested in the younger population
[12, 13]. In a study of younger IS patients (below ages 50 and
60 years, respectively), without other established vascular
risk factors, were more likely to have this gene mutation
as compared to the controls (6–7.6 versus 1–1.2%) [12].
However, another study of 131 patients with IS contradicted
these results and found that the prevalence of Prothrombin
gene mutation was similar to the control population [13].
3.3. Deﬁciencies in Coagulation Factors (Inherited Coagulop-
athies). Inherited coagulopathies are generally more com-
moninBlackAfricansandBlackCaribbeans,withorwithout
IS. In a prospective study of multiethnic population, black
African patients were found to have signiﬁcantly lower
protein S (P<. 001) protein C (P = .049), and antithrombin
III (P = .056) levels when compared to the whites [14].
SimilartrendswerenotedforproteinSdeﬁciencyinasmaller
study that reported its higher incidence in blacks than non-
blacks (34% versus 13%, P = .001) [15].
Protein C is one of the three key proteins that regulate
coagulation besides protein S and antithrombin III. It
is a vitamin K-dependent glycoprotein and its deﬁciency
presents in 2 forms. Type I deﬁciency has plasma protein C
concentration below 70% of the overall mean value. Type II
deﬁciency states are relatively less common and have normal
blood levels. However, the functional activity of protein C is
impaired. In general, the incidence of protein C deﬁciency
is 1 in 200 to 500 [16]. Nedeltchev et al. reported 0.5%
incidence rate of protein C deﬁciency in young IS patients
[10]. An association between young IS and inherited protein
C deﬁciency has been reported in individual case reports
[17]. However, larger studies failed to demonstrate this
relationship [18]. Protein C deﬁciency alone does not appear
to increase the risk or arterial thrombosis, slightly higher
incidenceofmyocardialinfarctionisnotedwhenitiscoupled
with other vascular risk factors [19, 20]. Uncommonly, some
physiological and disease states like pregnancy, drugs, severe
infection, and liver disease can produce an acquired protein
C deﬁciency.
Protein S acts as a cofactor for protein C. Isolated protein
S deﬁciency may be seen in up to 10% patients with young
IS. However, except for a few case reports, [21] signiﬁcant
relationship between this disorder and arterial thrombosis
has never been established [18]. Instead, most of the patients
with isolated protein S deﬁciency develop DVT, and they
usually do so before the age of 25 years.
Antithrombin deﬁciency occurs in 1 of 5000 healthy
blood donors [22]. Among patients with a ﬁrst thrombotic
event, the prevalence of this inherited disorder is approxi-
mately 0.5% to 1% [23, 24]. This protein may contribute to
thrombotic events either by being deﬁcient or dysfunctional.
Again, direct association of antithrombin deﬁciency with
arterial thrombosis remains controversial [22, 24].
3.4. Disorders That Are Polygenic and Interact with Dietary
or Environmental Factors. Cross-sectional and observational
epidemiological studies have suggested that elevated plasma
homocysteine concentrations might constitute a higher risk
for major thrombotic events [25–27]. Some randomized
trialsdemonstratedthathomocysteinelevelsinthebloodcan
be lowered by treatment with B vitamins and folic acid [28].
Homocysteine metabolism may be impaired due to genetic
(abnormal enzymes in its metabolic pathway) as well as
nutritional factors (vitamin B6, folate, and B12 deﬁciencies).Stroke Research and Treatment 3
The most common genetic mutation of hyperhomocysteine-
miaisaC-to-Tsubstitutionofnucleotide677(C677T)ofthe
gene 5,10-methylenetetrahydrofolate reductase (MTHFR).
The VITATOPS, a randomized, double-blind, placebo-
controlled trial involving 8164 patients, recently tested the
homocysteine-lowering multivitamin therapy in patients
with transient ischemic attacks or strokes [29]. The study
concluded that the daily administration of folic acid, vitamin
B6, and vitamin B12 in patients with recent stroke or
transientischemicattackwassafebutdidnotreducetheinci-
dence of major vascular events as compared to the placebo.
4. AcquiredThrombophilic Disorders
4.1. Antiphospholipid Antibody Syndrome. The most com-
mon acquired thrombophilic disorder is antiphospholipid
syndrome (APS). APS is a multisystem autoimmune dis-
order which can be either primary or secondary to other
autoimmune diseases. It occurs more commonly in females
and is characterized by arterial and venous thrombosis. It
is associated with antiphospholipid antibodies such as lupus
anticoagulant and anticardiolipin antibodies. A case control
studysuggestedthatlupusanticoagulantisamajorriskfactor
for arterial thrombotic events in young women and found
17% of patients with IS as tested positive for the antibody
[30]. Lupus anticoagulants are considered to carry a 5 to 16
times higher risk for thrombotic events than anticardiolipin
antibodies [31].
4.2. Diagnosis of APS. APS can be diagnosed based on an
international consensus criteria which was designed mainly
for application to clinical studies of APS, and its diagnosis
is based on clinical criteria of one or more occurrence of
pregnancy morbidity or vascular thrombosis, and laboratory
criteria of the presence of antiphospholipid antibodies on
two or more occasions at least 12 weeks apart [32].
4.3. Laboratory Measurement of Antiphospholipid Antibodies.
Consensus guidelines recommend screening for lupus anti-
coagulants (LA) with 2 or more phospholipid-dependent
coagulation tests, which is best done when the patient is
not receiving oral anticoagulants or unfractionated heparin,
which can result in prolonged clotting times and subsequent
false-positive results [33]. Both anticardiolipin antibodies
and anti-β2-glycoprotein I antibodies can be detected using
enzyme-linked immunosorbent assay (ELISA) techniques,
but many of these assays are not standardized. Consensus
guidelines recommend semiquantitative reporting of anti-
cardiolipin antibody results (low, medium, or high titer)
[34].
4.4. Antithrombotic Treatment of APS for Patients with
Arterial Thromboembolism. The choice of antithrombotic
treatment is still controversial due to the lack of randomized
treatment trials. Treatment choices should be individualized
by balancing the risk of thrombosis and hemorrhage of each
patient. Generally, the most common presentation of arterial
thromboembolism in APS is ischemic stroke (13%), and
transientischemicattack(7%)ofpatientsmeetingconsensus
diagnosticcriteria[35].Thepresenceoflupusanticoagulants
or anticardiolipin antibodies have also been found to be
associated with a 2-fold increase in ﬁrst ischemic stroke [36].
The APASS study (APL and Stroke Study), [37]w a s
a prospective cohort study within the Warfarin Aspirin
Recurrent Stroke Study (WARSS), which was a randomized
double-blind study comparing warfarin and aspirin for
preventing recurrent stroke or death [38]. They found that
patients treated with warfarin had a similar relative risk of
recurrent ischemic stroke or death as patients treated with
aspirin, and there was no diﬀerence whether patients were
tested positive or negative for antiphosphospholipid anti-
bodies[37].Basedonthis,antithromboticrecommendations
have been that both warfarin and aspirin are reasonable ﬁrst
choice antithrombotic treatments for patients presenting
with a ﬁrst ischemic stroke, with aspirin having the beneﬁt
of a lower bleeding risk and not requiring regular INR
monitoring [39]. However, it should be noted that the
median INR achieved in this study by the patients on
warfarin was 1.9. There are currently no studies evaluating
the optimal duration of treatment, and so patients are often
treated indeﬁnitely, similar to those patients with venous
thromboembolism [39].
4.5. Heparin-Induced Thrombocytopenia. Heparin-induced
thrombocytopenia (HIT) is another cause of transient
acquired thrombophilia. It is due to heparin-dependent
platelet activating immunoglobulin which further causes a
temporary hypercoagulable state through several mecha-
nisms. The risk of HIT-associated thrombosis ranges from
50% to 90%, with higher risk of thrombosis in the lower
platelet group [40]. Generally, venous thrombosis like deep
vein thrombosis and pulmonary embolism are most com-
mon, but arterial thrombosis including lower limb ischemia,
stroke, and myocardial infarction are also relatively common
[40].
4.6. Lipoprotein (a) and Stroke. Another important cause of
acquiredthrombophilia is lipoprotein (a).Itis aglycoprotein
attached to the LDL. In a prospective study, lipoprotein (a)
concentration was associated with chronic heart disease (risk
ratio of 1.16, 95%CI, 1.11–1.22) and ischemic stroke (risk
ratio of 1.10, 95%CI, 1.02–1.18) [41] .T h em e c h a n i s mi ss t i l l
unclear but increasing thrombosis and impaired ﬁbrinolysis
at the sites of plaque rupture are the possible causes [42].
4.7. Other Related Disorders That Increase the Risk of IS.
Presence of thrombophilic state typically predisposes a
patientpredominantlytovenousthrombosisandcarriesonly
a small risk for arterial thrombosis or IS. More typically, the
thrombophilic disorders contribute to DVT in lower extrem-
ities and pelvic veins travels and an embolus from them may
traverse through an atrial septal defect or patent foramen
ovale (PFO) to cause paradoxical cerebral arterial emboliza-
tion [43]. In a series with 125 young IS patients (age 34±7.3
years), the PT G20210A variant and FV G1691A mutation
were more frequent in the PFO positive group compared to
thecontrols(PFOnegative)[44]. However, the phenomenon









Right    POP V 55 W/COMP






























Figure 1: A 27-year-old woman, without any vascular risk factors, presented with mild right-sided weakness of suddenonset. She was noted
to have swelling and pain in the right leg. Duplex sonography revealed extensive deep vein thrombosis involving the popliteal as well as
superﬁcial femoral vein, as characteristic noncompressibility and echogenic mass in the venous lumen. (a) Computerized tomographic
angiography of thorax revealed ﬁlling defect in the left pulmonary artery. (b) Transcranial Doppler ultrasonographic monitoring of left
middle cerebral artery during the “bubble test” (injection of agitated 9mL normal saline and 1mL air) revealed numerous microembolic
signals, (c) suggestive of a right-to-left shunt (patent foramen ovale). Multiple acute ischemic infarcts involving many arterial territories
were evident on the diﬀusion-weighted magnetic resonance imaging of the brain. (d) Blood tests were positive for lupus anticoagulant and
anticardiolipin antibodies.
hypothetical. Various epidemiological studies have reported
an increased incidence of PFO in cryptogenic stroke patients
as compared to the general population. Since cerebral
embolization through a PFO is considered to be the possible
etiological mechanism, identiﬁcation of the presence of a
venous thrombus and its migration via the PFO are essential
to conﬁrm this pathogenic mechanism. However, both of
these essential components are often diﬃcult to establish
due to various methodological and temporal issues [45].
Imaging ﬁndings in a patient with thrombophilia, extensive
deep vein thrombosis, pulmonary embolism as well as
multiple cerebral ischemic infarctions due to paradoxical
embolization through a PFO are shown in Figure 1.
4.8. Synergisms. We believe that acute IS in young throm-
bophilic patients is the result of interaction between the
underlying genetic disorder and environmental factors. This
interactionmightinﬂuencethestrokeseverityalso.Common
environmental factors that are believed to increase the
risk of thrombotic events in patients with relevant genetic
disorders include smoking, hypertension, dyslipidemia, and
diabetes mellitus. In a study that looked at the cumulative
eﬀect of some of the inherited thrombophilias and their
interactions with modiﬁable predisposing factors (smoking,
hypertension), the odds for IS were 1.73 in subjects with one
polymorphism. The risk increased to 3.00 if the subjects had
two or more polymorphisms [46].
Oral contraceptive pills are believed to increase the risk
of venous thrombotic events and, at times even IS, especially
in patients with thrombophilia [47]. In a case-control study
on women less than 45 years old with a ﬁrst IS, oral contra-
ceptivesdoubledtheriskofISintheﬁrst6–18monthsofuse.Stroke Research and Treatment 5
The risk increased dramatically to 13 times higher in patients
who were also carriers of Factor V Leiden mutation and 9
times higher with coexistent hyperhomocysteinemia [48].
5. The Controversy of
Testing for Thrombophilia
Young IS patients, especially those without the common
vascular risk factors and classiﬁed as “strokes of undeter-
mined etiology” [2], are usually investigated for uncommon
causes,withspecialemphasisonthrombophilicdisorders.As
a result, up to a third of all IS patients may undergo a barrage
of tests for various thrombophilic states [49]. However,
indiscriminate ordering of these tests is often debatable. The
cost of this gamut of tests can run up to more than $1000
US dollars in the United States [49], US $500 in the United
Kingdom, and US $200 in Australia [50]. Apart from the
high cost, these tests generate some psychological impact on
the patients and their families, especially due to the possible
genetic component [51]. Potential psychological and social
consequences include fear, depression and worry [51], and
diﬃculty of getting life or disability insurance in the future if
the tests show an abnormal result [52].
The actual beneﬁt of routine testing for thrombophilic
disorders in IS remains uncertain [49, 50, 53]. The primary
aims of testing for these uncommon disorders are to
ascertain the deﬁnite diagnosis, possible prognostication,
and to provide an appropriate treatment as well as secondary
prophylaxis. Furthermore, primary prophylaxis may also
be oﬀered to family members of the proband who are
carriers of a particular genetic defect but have not yet had
a symptomatic thrombotic event [54]. However, the yield of
performing extensive diagnostic tests is often poor and, in
the majority of cases, no established curative measures exist.
6.Who Should be Screened?
The prevalence of thrombophilic disorders among the gen-
eral population is low [7–10]. Furthermore, even when they
occur with a higher prevalence (Factor V Leiden and pro-
thrombin gene mutations in Caucasians), the thrombophilic
states may not carry an alarmingly increased risk of throm-
boembolism [54]. The acquired thrombophilic disorders
(lupus anticoagulant and anticardiolipin antibodies) confer
a relatively higher risk for arterial thrombosis and IS [31].
However, the inherited thrombophilic disorders account for
a very low thrombotic risk [6, 54, 55]. Furthermore, the
prevalence of various thrombophilic disorders is very low in
some ethnic groups of African or African-Caribbean descent
[6, 54, 55]. Therefore, it has generally been believed that the
routine screening of the general population is not justiﬁed.
Morris et al., in their analysis of the case-control studies
of the 5 most commonly inherited thrombophilias with
ischemic stroke: protein C and S deﬁciencies, antithrombin
deﬁciency,factorVLeidenandprothrombingenemutations,
found no convincing associations with stroke, even in young
patients and patients with patent foramen ovale [56]. In
light of this, they have recommended that patients without
a white ancestor should not be tested for Factor V Leiden
or Prothrombin and that levels of protein C and protein
S should be interpreted cautiously in those of African
descent. They also recommended that cryptogenic stroke
patients with patent foramen ovale should be investigated
for deep venous thrombosis in the legs and pelvic veins. As
part of their recommendations, investigating for inherited
thrombophilias should be done in patients having any of the
other clinical features necessitating a thrombophilic workup
as set out by WHO recommendations: history of venous
thromboembolism—either unprovoked or in unusual loca-
tion, family history of venous thromboembolism, throm-
bosis at a young age (less than 45 years old), and frequent
thrombotic recurrences [57].
Walker et al. [6] observed a nonsigniﬁcant trend towards
a higher prevalence of thrombophilia, especially in 20.5%
of IS classiﬁed as “cardioembolic stroke” according to the
TOAST classiﬁcation [2]. The study postulated that the
hypercoagulable state promoted the development of “red”
ﬁbrin thrombi in areas of stasis such as veins and heart
chambers. These “red” clots were considered rich in ﬁbrin
and diﬀered from the usual “white” clots, rich in platelet
content, that develop in arteries [6]. Similarly, Carod-Artal
et al. [58] found that prothrombotic conditions were more
frequent among the young IS patients classiﬁed as “strokes
of undetermined cause” [2]. However, they did not observe
any association between inherited thrombophilic disorders
and any of the pathogenic subtypes of IS among the older
patients. Interestingly, isolated protein S deﬁciency was
associated with “stroke of undetermined cause” in the young
patients.
Selection of patients for performing various diagnostic
tests for the thrombophilc disorders should not be inﬂu-
enced by IS involving a speciﬁc vascular territory. For
example,anteriorcerebralartery(ACA)territoryinfarctions,
comprising less than 3% of IS, are usually considered
cardioembolic in origin [59]. Stroke in ACA territory are,
therefore,ofteninvestigated foranunderlying cardioembolic
or thrombophilic cause. However, in some ethnic popu-
lations, especially Chinese, ACA may be involved in the
generalizedatheroscleroticprocess[60].ISresultingfromthe
thrombophilic disorders might involve any arterial territory
and often aﬀects multiple arterial territories together [61].
The more useful and practical approach of ordering various
diagnostictestsfortheuncommonthrombophilicstatestests
should be determined by a detailed clinical history, phys-
ical examination, imaging studies and evaluating whether
an underlying hypercoagulable state appears more likely.
History of a prior thromboembolic event, especially that
occurred after minimal stimuli or at unusual sites is an
important clue for thrombophilic disorders [62]. Similarly,
venous thrombosis is the most common manifestation of
coagulopathy[63]whileahistoryofunexplainedmiscarriage
may signify the presence of antiphospholipid syndrome [64].
Some other clues that might suggest the presence of a
thrombophilic disorder include thrombocytopenia, livedo
reticularis, or Sneddon syndrome (skin necrosis during
initiation of oral anticoagulant therapy), family history of
clotting events at a young age, absence of conventional6 Stroke Research and Treatment
vascular risk factors, presence of malignancy or sepsis, and
recurrent thrombotic events despite appropriate treatment
[65]. History of previous venous thrombosis and miscar-
riage is the most important fact that is often missing in
patients’ medical records which leads to a delay in diagnosis
[49].
An important factor that should be used in selecting
patient for testing the thrombophilic disorders is age. While
thrombophilia is rarely associated with arterial occlusive
disease in adults, it constitutes an important cause in
childhoodandyoungIS.Accordingly,Duranetal.foundthat
57% of pediatric IS patients tested positive for at least one
thrombophilic marker as compared to 15% of age-matched
controls [66]. Furthermore, 10% of the pediatric population
had 2 or more positive markers. Similarly, a high prevalence
of antiphospholipid syndrome is observed in children with
idiopathic cerebral ischemia [67], with 76% of children
aged 5 to 16 years tested positive for lupus anticoagulant
or anticardiolipin antibodies. However, it should always
be kept in mind that atherosclerosis and cardioembolism
still constitute more likely causes [68] as compared to the
thrombophilic disorders that account for only 10% to 15%
of the cases of IS in the young [3]. In another study of
subjects less than 18 years of age, half to two thirds of IS
demonstrated thrombophilic states [69]. Considering the
rarity of childhood IS, congenital heart disease would have
complemented multiple coexisting thrombophilic states in
causing the high prevalence of IS [69]. Finally, screening
for prothrombotic states should also be considered in
symptomatic siblings and ﬁrst-degree family members to
identify patients at relatively highrisk [70].
7. What Should be Screened?
Some young patients suﬀer from multiple thrombophilic
disorders that confer an additive or multiplicative risk of
thromboembolism. For example, the combined defects of
protein C or protein S deﬁciencies plus Factor V Leiden, or
the acquirement of hyperhomocysteinemia with Factor V
Leiden, increase the risk of thromboembolism compared to
eitherdefectinisolation.Similarly,acombinedantithrombin
III deﬁciency with Factor V Leiden mutation poses a very
high risk of thromboembolism when compared to either
defect alone. Therefore, the laboratory screening should be
comprehensive and avoid missing the coexisting defect [54].
Accordingly, functional assays for proteins C, protein S, and
antithrombin III should be performed if activated protein
C (APC) resistance is observed; prothrombin 20210A,
ﬁbrinogen, homocysteine, D-dimers, and factor VIII should
be tested carefully if there is coexisting ulcerative colitis
[71]. It is important that a diagnostic search protocol should
include tests for both inherited and acquired thrombophilic
disorders. Finally, assessment of plasma homocysteine has
been advised in all IS patients since it is considered easily
reversible with vitamin supplementation [71]. However, the
recently published VITATOPS trial failed to demonstrate any
signiﬁcant beneﬁcial eﬀects of this approach [29].
8.What Is the Appropriate
Timing for Screening?
Since the therapeutic approach (anticoagulation and throm-
bolytic therapy) determines the clinical outcomes, early
diagnosis of the thrombophilic disorders plays an important
role. Furthermore, the timing of test performance of some
of the thrombophilic defects (like protein C, protein S,
antithrombin III and ﬁbrinogen levels) is often critical
since these proteins can behave as acute phase reactants
and erroneously elevated levels of these factors may be
observed in patients with acute thrombotic events [54, 71].
Ontheotherhand,theplasmalevelsofvitaminK-dependent
proteins (protein C, protein S and APC resitance) may not
be reliable in patients taking vitamin K antagonists [72].
Similarly, antithrombin III measurements are unreliable in
patients receiving heparin. Therefore, it is suggested that
plasma-based assays for these disorders should be repeated
3 to 6 months after the initial thrombotic episode to
avoid false-positive results and avoid unnecessary prolonged
anticoagulation therapy. The assays for these disorders are
recommended after discontinuation of oral anticoagulant
treatment or heparin for at least 2 weeks [54, 71].
DNA-based assays are not aﬀected by acute thrombotic
events or use of anticoagulation and thrombolytic therapy.
Therefore, screening for these genetic mutations can be
performed reliably at any time following a thrombotic event
[54, 71].
Finally, natural history for some of the thrombophilic
disorders should be considered during the interpretation of
their diagnostic assays. Accordingly, lipoprotein (a) levels
increase during the ﬁrst year of birth. Hence, it is necessary
to repeat testing 8 to 12 months after the acute thrombotic
onset in neonates suﬀering from thromboembolism [71].
9. Factors to be Considered during the
Interpretationof DiagnosticTests
As mentioned above, the interpretation of the tests for some
of the thrombophilia markers depends on its timing in
relation to the acute thrombotic event as well as concurrent
medications, especially vitamin K antagonists and heparin.
In addition, patients’ age also might aﬀect the results of
some these markers. For example, antithrombin III levels
decline with increasing age, and the reference range may
therefore need some adjustments accordingly [6]. Another
important factor that may alter the results is patients’
ethnicity. The conventionally employed reference ranges for
some biomarkers of thrombophilia may lead to false positive
diagnoses in black Africans or black Caribbeans due to
their inherent lower concentrations when compared to the
Caucasian population [14].
The presence of concomitant medical conditions and
drug therapies should also be taken into consideration dur-
ing the interpretation of results. For example, antithrombin
III levels can be relatively lower in liver disease, nephritic
syndrome,inﬂammatoryboweldiseasesandpregnancy;liver
disease can be associated with lowered protein C and S levels;
pregnancy can result in lowered protein S levels and acquiredStroke Research and Treatment 7
APC-resistance. Furthermore, protein S levels and the
acquired APC resistance may be aﬀected by sex-hormonal
treatment in females [72]. Correct interpretation of anticar-
diolipin antibody titers can also be diﬃcult in some patients,
as the blood levels can be aﬀected by other conditions such
as viral, bacterial or parasitic infections, lymphoproliferative
disorders, paraproteinemia, or drugs such as phenothiazine,
procainamide, phenytoin, quinidine and hydralazine [73].
Therefore,otherclinicalorlaboratoryfeaturesofAPSshould
be sought for an accurate diagnosis [43].
10.What Secondary Stroke Prevention
Method Should be InstitutedIfthe
ScreeningIs Positive?
In the event that the screening was done indiscriminately
for a stroke patient, it is reasonable to ﬁrst interpret the
results with caution. One must ﬁrst evaluate whether a more
obviousstrokemechanismispresent,orwhetheracoexisting
condition is already present which would already necessitates
the use of anticoagulation, for example a cardioembolic
source. The results should also be assessed if they are truly
positive, for example if the protein C or S levels were drawn
shortly after an acute thrombosis, or if the blood test were
done with patient still on anticoagulant therapy. Lastly, one
should interpret the signiﬁcance of the positive result in
light of the patient’s cardiovascular risk proﬁle and age,
for example, it would have greater implications in a young
patient without cardiovascular risk factors [74].
Treatment of an ischemic stroke is not as clearly deﬁned
as that for venous thromboembolism in all of the inherited
thrombophilias. Acute venous thromboembolism is treated
with heparin or low-molecular-weight heparin and then
warfarin to achieve a target INR of 2.0 to 3.0 for at least 6
months to an indeﬁnite period of time [57]. For ischemic
stroke, however, there is only 1 prospective observational
study comparing cryptogenic stroke patients with and
without thrombophilia, and the use of anticoagulation did
not aﬀect outcomes [75].
Oral anticoagulation is therefore not recommended for
asymptomatic carriers of these defects, though symptomatic
patients may possibly be treated in the same way as that
of venous thromboembolism, though anticoagulation may
be avoided in the acute phase due to the concerns for
hemorrhagic transformation of the infarction [56].
11. Conclusion
Our understanding of various mechanisms for thromboem-
bolism has improved considerably in the past decade.
Furthermore, the diagnostic tests have become simpler,
cheaper, faster, more reliable, and widely available. Low
prevalence and diagnostic yield of various thrombophilic
disorders does not support strongly the routine screening
of the general population. However, a careful selection of
high-risk patients, the timing of testing, and the type of tests
often contribute towards appropriate therapeutic decision
making [76]. Future research in this ﬁeld would improve
our understanding about various thrombophilic disorders
and aid in developing optimal therapeutic and preventive
strategies for younger ischemic stroke patients.
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